Inhibrx Announces Details of Presentation at 2022 ASCO Annual Meeting

SAN DIEGO, May 19, 2022 /PRNewswire/ — Inhibrx, Inc. (Nasdaq: INBX), a biotechnology company with four clinical programs in development and an emerging pre-clinical pipeline, announced today that it will be presenting details on the trial design for the INBRX-109 Phase 2 potentially…

Click here to view original post